8-K

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 8-K
CURRENT REPORTPursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934Date of Report (date of earliest event reported): October 28, 2013

BioTime, Inc.
(Exact name of registrant as specified in its charter)

California	1-12830	94-3127919
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1301 Harbor Bay Parkway
Alameda, California 94502
(Address of principal executive offices)

(510) 521-3390
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Forward-Looking Statements

Any statements that are not historical fact (including, but not limited to statements that contain words such as “may, “will,” “believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements.  Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in BioTime’s periodic reports filed with the SEC under the heading “Risk Factors” and other filings that BioTime may make with the Securities and Exchange Commission.  Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change.  Except as required by law, BioTime disclaims any intent or obligation to update these forward-looking statements.

This Report and any accompanying exhibits shall be deemed “furnished” and not “filed” under the Securities Exchange Act of 1934, as amended.

Section 7 - Regulation FD

Item 7.01 - Regulation FD Disclosure

On October 28, 2013, BioTime, Inc. issued the press releases furnished as Exhibits 99.1 and 99.2, which are incorporated by reference.

Section 9-Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press Release Dated October 28, 2013.
99.2	Press Release Dated October 28, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		BIOTIME, INC.
Date:	October 28, 2013		By:	/s/ Michael D. West
			Chief Executive Officer

2

Exhibit Number	Description
99.1	Press Release Dated October 28, 2013.
99.2	Press Release Dated October 28, 2013.

3

EX-99.1

Exhibit 99.1

BioTime, Inc. to Provide Company Updates During Investor Day, October 28, 2013

ALAMEDA, Calif.--(BUSINESS WIRE)--October 28, 2013--BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding its annual Investor Day providing company updates at the Harvard Club in New York City. The presentations will be available on the company website, www.biotimeinc.com.

Thomas Okarma, M.D., Ph.D., President and CEO of Asterias Biotherapeutics Inc., will present a summary of Asterias, a new subsidiary of BioTime. Asterias recently acquired Geron Corporation’s human embryonic stem cell assets, as well as certain assets from BioTime, including rights to use certain human embryonic stem cell lines developed by BioTime’s subsidiary ES Cell International Pte Ltd., minority stakes in two of BioTime’s other subsidiaries, and BioTime common shares.

William Tew, Ph.D., BioTime’s Chief Commercial Officer will provide an update on the development of Renevia™. In his presentation, Dr. Tew will announce that enrollment in a safety trial evaluating Renevia™, a proprietary injectable matrix designed to facilitate the stable engraftment of transplanted cells, is complete and the initial ten subjects who each received one subcutaneous injection of Renevia™ have been followed for three weeks after treatment and to date, Renevia™ has been well-tolerated by all patients with no serious adverse events.

BioTime will also describe new work using BioTime’s HyStem^® technology to develop 3D cell culture platforms for improved methods of screening new anti-cancer drug candidates in a project funded by a research grant from the National Institutes of Health.

Charles S. Irving, Ph.D., the CEO of BioTime’s subsidiary Cell Cure Neurosciences Ltd. will provide an update on the development of OpRegen^®. In his presentation, Dr. Irving will describe the unmet medical needs and markets for the treatment of the dry form of age-related macular degeneration (AMD), and the advantages of Cell Cure’s OpRegen^® which has been produced from human embryonic stem cells in culture conditions free of animal products, eliminating the need for designating the product as a xenotransplantation therapeutic. Dr. Irving’s presentation will contain assessments of Cell Cure’s approach by key opinion leaders in the fields of macular degeneration and human embryonic stem cell research. Dr. Irving will describe the progress of the ongoing preclinical studies which are expected to lead to regulatory filings for the initiation of human clinical trials in 2014.

Joe Wagner, Ph.D., the CEO of BioTime’s subsidiary OncoCyte Corporation will provide an update on development of the Company’s PanC-Dx™ family of cancer diagnostic products. Dr. Wagner will describe genomic and proteomic technology developed at OncoCyte that forms the basis of these products. His talk will include information on plans for clinical trials of PanC-Dx™ in breast cancer and bladder cancer screening and new planned clinical trial in mammography patients and the recently announced lung cancer study being conducted with The Wistar Institute.

David Warshawsky, the CEO of BioTime’s subsidiary LifeMap Sciences, Inc., will provide an update on LifeMap’s business. He will report on the Integrated Biomedical Knowledgebase and discovery platform for biomedical research, including GeneCards^®, LifeMap Discovery™ and MalaCards.

Francois Binette, Ph.D., the Vice President of Research and Business Development of BioTime’s subsidiary OrthoCyte Corporation, will describe the discovery effort at OrthoCyte focusing on the development of novel regenerative therapeutics for various orthopedic diseases and injuries. Dr. Binette will also describe some of the promising results obtained with the collaboration of University of California San Diego Prof. Koichi Masuda M.D., Director of Skeletal Translational Research Laboratory, Department of Orthopaedic Surgery, School of Medicine, using progenitor OTX-05,-07,-09 in an ex vivo model for degenerative disc disease, the principal cause of chronic back pain. Chronic back pain is one of the largest health economics burden in modern societies since there are no treatment or cure for a condition that affects more than 85% of the population in their lifetime.

David Larocca, Ph.D., the recently appointed vice president of research and development of BioTime’s subsidiary ReCyte Therapeutics, Inc., will provide an update on the development of vascular progenitor cells for the treatment of heart disease.

About BioTime, Inc.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime’s focus is on pluripotent stem cell technology based on human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime’s therapeutic and research products include a wide array of proprietary PureStem™ progenitors, HyStem^® hydrogels, culture media, and differentiation kits. BioTime is developing Renevia™ (a HyStem^® product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend^®, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend^® is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

• OncoCyte Corporation is developing products and technologies to diagnose and treat cancer.
• ES Cell International Pte Ltd., a Singapore private limited company, develops hES products for research use.
• BioTime Asia, Limited, a Hong Kong company, may offer and sell products for research use for BioTime’s ESI BIO Division.
• OrthoCyte Corporation is developing therapies to treat orthopedic disorders, diseases and injuries.
• ReCyte Therapeutics, Inc. is developing therapies to treat a variety of blood and lymphatic vascular disorders, as well as products for research using iPS and other cell reprogramming technology.
• Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company focused on developing stem cell-based therapies for retinal and neurological degenerative diseases. Its lead product is OpRegen^® for the treatment of macular degeneration.
• LifeMap Sciences, Inc. markets, sells and distributes GeneCards^®, the leading human gene database, as part of an integrated database suite that also includes the LifeMap Discovery™ database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database.
• Asterias Biotherapeutics, Inc. is a new subsidiary that recently acquired the stem cell assets of Geron Corporation, including patents and other intellectual property, biological materials, reagents and equipment for the development of new therapeutic products for regenerative medicine.

Additional information about BioTime can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com

CONTACT:
BioTime, Inc.
Lesley Stolz, PhD
Executive Vice President, Corporate Development
510-521-3390, ext 367
lstolz@biotimemail.com
or
Judith Segall
510-521-3390, ext 301
jsegall@biotimemail.com

EX-99.2

Exhibit 99.2

Asterias Biotherapeutics, Inc. Plans to File Registration Statement for Underwritten Public Offering

MENLO PARK, Calif. & ALAMEDA, Calif.--(BUSINESS WIRE)--October 28, 2013--Asterias Biotherapeutics, Inc., a majority-owned subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that it plans to file a registration statement with the Securities and Exchange Commission in November 2013 for an underwritten public offering of units, with each unit consisting of one share of Series B common stock, $0.0001 par value per share, and one redemption right in respect of one share of Series B common stock. The shares of Series B common stock and redemption rights will immediately separate after purchase and will be freely tradable as separate securities after the closing of the offering.

Asterias plans to use the net proceeds of the offering, expected to be between $12 million and $15 million, to fund its product development programs and for working capital. Asterias plans to apply to list the Series B common stock on the NYSE MKT under the symbol AST. Prices for the redemption rights are expected to be quoted on the OTC Bulletin Board. The number of units to be offered and the price range for the units have not yet been determined.

Each redemption right will entitle the holder to sell one share of Series B common stock to Asterias during a redemption period that will commence 30 days prior to the third anniversary of the closing of the offering and that will end on that third anniversary date. If a share of Series B common stock is redeemed through the exercise of a redemption right, Asterias will pay the shareholder either an amount of cash or shares of common stock, no par value, of its parent company, BioTime, Inc. (“BioTime”), or a combination of cash and BioTime common stock, with a value equal to the initial public offering price of the Asterias Series B common stock. The decision whether to pay the redemption price in cash or BioTime common stock will be made by the Board of Directors of Asterias in its discretion at the time of any redemption. The redemption rights will expire on the earlier of (a) the third anniversary of the closing of the offering, and (b) the date, if any, on which the closing price of the Asterias Series B common stock, as reported on a national securities exchange or the OTC Bulletin Board, has been at least 150% of the redemption price for 10 consecutive trading days. Redemption rights will not be exercisable after they expire.

Asterias plans to file a registration statement relating to these securities with the Securities and Exchange Commission relating to these securities during November 2013. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities or any BioTime securities; nor shall there be any offer or sale of any of such securities in any state in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Asterias

Asterias Biotherapeutics is a subsidiary of BioTime, Inc., whose first acquisition was the stem cell assets of Geron Corporation, which was completed on October 1, 2013. That acquisition includes Geron’s entire cell therapy intellectual property portfolio, existing contracts and license agreements related to their stem cell programs, INDs for OPC1 and VAC1 cell therapies, master cell banks of hESCs and therapeutic cells manufactured under cGMP, research cell banks, customized reagents and equipment, and banks of cGMP-manufactured OPC1 drug product used in Geron’s Phase 1 trial in subacute spinal cord injury, the world’s first human clinical trial of hESC-derived cells.

CONTACT:
Asterias Biotherapeutics, Inc.
Thomas Okarma, MD, PhD, 650-433-2900
President & CEO
tokarma@asteriasbio.com